European Approval of azacitidine tablets (Onureg) for frontline oral maintenance therapy for adults with acute myeloid leukaemia

Approval based on results of phase III QUAZAR® AML-001 RCT (n=472) which found oral azacitidine increased overall survival and relapse free survival vs placebo (24.7 vs 14.8 months, and 10.2 vs 4.8 months respectively; p<0.001 for both).

Source:

Biospace Inc.